Snigdha Tenneti joined Neurvati as an intern and has been part of the team ever since. Hear her story and what it means to work to advance research for rare neurodevelopmental disorders.

What's the biggest driver of progress in rare neuroscience today?

For #ChildrensHealthMonth, we recognize the importance of advancing research for children and families navigating rare neurodevelopmental disorders. Read 3 things to know about these conditions.

Neuroscience drug development is increasingly grounded in scientific precision. Our CEO Bruce Leuchter, M.D., explores what this shift means from genetically defined neurodevelopmental disorders to investor dynamics in this @DDWonline article (pp. 56-57): bit.ly/4rF99j7

On #WorldPatientSafetyDay, we reaffirm our commitment to advancing research for rare neurodevelopmental disorders with participant safety and caregiver trust at the center of everything we do. @GRIN_tx

Recent setbacks in social anxiety disorder aren't a lack of therapeutic opportunity. CEO Bruce Leuchter, M.D., shares his perspective with @pharmavoice on why mechanism, patient heterogeneity, trial design, and novel approaches hold real promise. bit.ly/4gIqZ0J

Our CEO, Bruce Leuchter, M.D., discusses how biology-led development, better diagnosis, and #RareDisease infrastructure can help accelerate the development of the next generation of #neuroscience therapies. Read the Manufacturing Chemist interview: bit.ly/4xpGOyL

We're pleased to announce J. Michael Ryan, M.D., as Chief Medical Officer, and the promotions of Anne-Marie Li-Kwai-Cheung to Chief Development Officer and Elliott Ruiz to Chief Financial Officer. Read the full announcement: bit.ly/4hg3exN

We stand alongside @wfneurology to observe #WorldBrainDay and this year's theme, #AccessForAll. It aligns with our mission to advance therapies for patients and families impacted by serious pediatric neurodevelopmental disorders: bit.ly/4pBSn3h

This #MothersDay, we celebrate the strength, compassion, and dedication of mothers everywhere. Through our affiliate @GRIN_Tx, we see how mothers of children with rare neurodevelopmental disorders advocate and support their families every day.

This #MentalHealthAwarenessMonth, we honor the courage, strength, and perseverance of every patient and family member and reaffirm our commitment to supporting them achieve more good days, together.

In recognition of #AdministrativeProfessionalsDay, we take a moment to celebrate the backbone of our organization – our incredible administrative professionals. Hear from Nicole Tantillo about the impact our administrative team has on the work we do.

On #WorldHealthDay, we reflect on the importance of equitable access to health advances and the collective effort it takes to transform scientific discovery into meaningful impact for patients and families.

Today, we join the @DanaFoundation in recognizing #BrainAwarenessWeek, celebrating progress in understanding, diagnosing, and treating neurological disorders. Thank you for shining a spotlight on the vital role of brain research. Learn about their work: dana.org/brain-awareness-wee…

At Neurvati & @GRIN_tx, women drive progress in neuroscience every day. On #IWD2026, we celebrate their expertise, leadership, & dedication. You show us every day that when we give with intention & purpose, patients, families & the entire scientific community all benefit.

On #EmployeeAppreciationDay, we celebrate the talented and dedicated people whose hard work and collaboration drive everything we do at Neurvati and @GRIN_tx. Every milestone reflects their expertise, passion, and dedication to improving the lives of patients and their families.

Continuing with reflections from the Neurvati team as #RareDiseaseDay approaches: partnership matters and working with patients and advocates helps guide decisions and keeps development focused on real-world impact.

As neuroscience looks toward 2026, rare neurodevelopmental diseases remain a key area of focus. Our CEO Bruce Leuchter, M.D., shares his perspectives with @PharmExec: pharmexec.com/view/trends-ne…